MedTrace Logo

A Study to Evaluate THB001 in Adult Patients With Chronic Cold Urticaria

NCT05510843 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2023-10-10

No results posted yet for this study

Summary

This is a phase 1b, open label, non-randomized, sequential dose-escalation, multicenter trial in adult patients with chronic cold urticaria.

Conditions

  • Chronic Cold Urticaria

Interventions

DRUG

THB001

100 mg capsules for oral administration

Sponsors & Collaborators

  • Third Harmonic Bio, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-06
Primary Completion
2023-03-30
Completion
2023-04-04

Countries

  • Germany
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05510843 on ClinicalTrials.gov